46.16
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Can Supernus Pharmaceuticals Inc. stock resist market sell offsRate Hike & Scalable Portfolio Growth Ideas - Newser
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Popularity With Investors Is Under Threat From Overpricing - 富途牛牛
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics ... - Enidnews.com
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference - GlobeNewswire
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo! Finance Canada
Responsive Playbooks and the SUPN Inflection - news.stocktradersdaily.com
Is Supernus Pharmaceuticals Inc. stock overvalued by current metricsDay Trade & Free Accurate Trade Setup Notifications - BỘ NỘI VỤ
Supernus Pharmaceuticals Inc Stock Analysis and ForecastMerger & Acquisition Updates & Buy Sell Signal Notifications - earlytimes.in
Reversal Confirmed Inter Globe Finance Limited Stock Rallies Above MAStock Price Forecasts & High Return Capital Gain - earlytimes.in
Supernus Pharmaceuticals (SUPN) Is Down 17.4% After Raising 2025 Guidance Amid Margin and Supply Pressures – Has the Bull Case Changed? - Sahm
Is Supernus Pharmaceuticals Inc a good long term investmentChart Pattern Recognition & Small Budget Trading Portfolio - earlytimes.in
What analysts say about Supernus Pharmaceuticals Inc stockEconomic Data Impact & Outstanding Return Stocks - earlytimes.in
SUPN insider Form 4 shows 15,000-share option exercise at $12.98 - Stock Titan
Assessing Supernus Pharmaceuticals After FDA Pipeline News and 24% Jump in 2025 - Yahoo Finance
Healthcare Stocks Analysis 2025: COO & SUPN to Sell, HCA to BuyNews and Statistics - IndexBox
Assessing Supernus Pharmaceuticals (SUPN) Valuation as Shares Hold Steady Following Period of Range-Bound Trading - Sahm
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - Yahoo Finance
How Supernus Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Update & Expert Curated Trade Ideas - newser.com
Supernus to acquire depression drugmaker Sage - MSN
Why Supernus Pharmaceuticals Inc. stock could benefit from AI revolutionQuarterly Trade Summary & Growth Focused Entry Point Reports - newser.com
Understanding the Setup: (SUPN) and Scalable Risk - news.stocktradersdaily.com
Advanced analytics toolkit walkthrough for Supernus Pharmaceuticals Inc.Sell Signal & Expert Approved Trade Ideas - newser.com
Statistical indicators supporting Supernus Pharmaceuticals Inc.’s strengthJuly 2025 Earnings & Fast Moving Stock Watchlists - newser.com
Measuring Supernus Pharmaceuticals Inc.’s beta against major indices2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com
Is Supernus Pharmaceuticals Inc. a candidate for recovery playJuly 2025 Price Swings & Capital Efficient Trade Techniques - newser.com
How Investors Are Reacting To Supernus Pharmaceuticals (SUPN) Raising 2025 Revenue Guidance Despite Net Losses - simplywall.st
Supernus at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com Australia
SUPN: Strong CNS portfolio growth, supply challenges for Onapgo, and active business development focus - TradingView
[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Long term hold vs stop loss in Supernus Pharmaceuticals Inc.2025 Macro Impact & Technical Confirmation Alerts - newser.com
Using data models to predict Supernus Pharmaceuticals Inc. stock movementJobs Report & Weekly Momentum Stock Picks - newser.com
How to monitor Supernus Pharmaceuticals Inc. with trend dashboardsWeekly Investment Summary & Community Consensus Stock Picks - newser.com
Supernus Pharmaceuticals (SUPN): Assessing Valuation After Q3 Revenue Growth and Raised Guidance Despite Net Loss - Sahm
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):